Temovate (clobetasol propionate) is a high-potency topical corticosteroid indicated for the short-term treatment of moderate to severe inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. As a Class I super-potent steroid, it represents one of the most efficacious topical anti-inflammatory agents available by prescription. Its molecular structure enables enhanced lipophilicity and receptor binding affinity, facilitating rapid penetration and pronounced vasoconstrictive activity. Clinicians reserve Temovate for cases where lower-potency corticosteroids have proven insufficient, recognizing its powerful immunosuppressive and antiproliferative effects on cutaneous pathology.

Features

• Contains 0.05% clobetasol propionate USP in optimized vehicle formulations
• Available as cream, ointment, solution, foam, and shampoo for varied anatomical sites
• Enhanced epidermal penetration technology for targeted delivery
• Alcohol-free formulations available for sensitive skin and mucosal regions
• Paraben-free and fragrance-free compositions minimize irritant potential
• Occlusive base in ointment formulation enhances hydration and drug absorption

Benefits

• Provides rapid relief from inflammation, erythema, and pruritus within 48–72 hours
• Reduces lichenification and plaque elevation in psoriatic and eczematous lesions
• Minimizes disease flare frequency through effective short-term intervention
• Offers formulation flexibility for different body regions and patient preferences
• Demonstrates superior efficacy compared to mid-potency corticosteroids in refractory cases
• Enables shorter treatment duration due to heightened pharmacological activity

Common use

Temovate is primarily prescribed for short-term management of psoriasis vulgaris, especially thick plaque psoriasis on non-facial, non-intertriginous areas. It demonstrates significant efficacy in treating recalcitrant cases of atopic dermatitis, lichen planus, discoid lupus erythematosus, and lichen simplex chronicus. Dermatologists may employ it for severe contact dermatitis when conventional therapies prove inadequate. Off-label uses include treatment of alopecia areata and keloids, though these applications require careful risk-benefit assessment due to the drug’s potency.

Dosage and direction

Apply a thin film to affected areas twice daily, gently rubbing until absorbed. The total weekly dosage should not exceed 50 grams for adults or proportionally less for pediatric patients. Treatment duration is typically limited to 2 consecutive weeks, with reassessment required before continuation. For scalp applications, apply solution sparingly to affected areas without saturating the scalp. Occlusive dressings may be used for resistant lesions under medical supervision but increase systemic absorption risk. Wash hands thoroughly after application unless treating hands.

Precautions

Avoid use on face, groin, axillae, or other intertriginous areas due to enhanced absorption and atrophy risk. Discontinue if irritation develops. Not recommended for use under diapers or plastic pants in children. Periodic evaluation for HPA axis suppression is advised during extended therapy. Patients should be monitored for signs of skin atrophy, telangiectasia, and striae, particularly in elderly patients with fragile skin. Use with caution in patients with liver impairment as metabolic clearance may be reduced.

Contraindications

Hypersensitivity to clobetasol propionate or any formulation components. Contraindicated in rosacea, perioral dermatitis, acne vulgaris, and cutaneous infections (viral, fungal, or bacterial). Not recommended during pregnancy unless potential benefit justifies potential risk to fetus. Avoid use in children under 12 years except under specialist supervision. Contraindicated in patients with untreated systemic infections or immunocompromised status.

Possible side effect

The most common adverse reactions include burning sensation, itching, irritation, and dryness at application site. Potential systemic effects include hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria. Local effects may include skin atrophy, striae, telangiectasia, contact dermatitis, hypopigmentation, and folliculitis. Secondary infections may occur due to immunosuppressive effects. Rare cases of generalized pustular psoriasis have been reported following withdrawal.

Drug interaction

No formal drug interaction studies have been conducted. However, concomitant use with other topical corticosteroids may increase systemic absorption and adverse effects. Use with other immunosuppressive agents may potentiate systemic immunosuppression. Interactions with CYP3A4 inhibitors (ketoconazole, erythromycin) may theoretically increase systemic exposure, though topical administration minimizes this risk.

Missed dose

Apply as soon as remembered unless close to next scheduled dose. Do not double application to make up for missed dose. Maintain regular application schedule without extra applications. If multiple doses are missed, contact healthcare provider for guidance on treatment resumption.

Overdose

Topical overdose may produce systemic effects including Cushing’s syndrome, hyperglycemia, and HPA axis suppression. Acute overdose requires discontinuation and symptomatic treatment. Chronic overdose manifests through signs of systemic corticosteroid excess. In case of accidental ingestion, seek medical attention immediately as gastrointestinal absorption may occur.

Storage

Store at controlled room temperature (20°–25°C or 68°–77°F). Keep tube tightly closed and away from excessive heat or moisture. Do not freeze. Keep out of reach of children. Discany unused product 30 days after opening to prevent contamination. Do not use if discoloration or separation occurs.

Disclaimer

This information does not replace professional medical advice. Treatment should be initiated and monitored by a qualified healthcare provider. Individual response may vary based on disease severity, application site, and patient factors. Use only as directed by prescribing physician. Report any adverse reactions to healthcare provider promptly.

Reviews

Clinical studies demonstrate 70–80% clearance rates in plaque psoriasis after 2 weeks of treatment. Dermatologists consistently rate Temovate as highly effective for resistant dermatoses, though emphasize the need for careful patient selection and monitoring. Patients report significant improvement in quality of life measures related to pruritus and appearance. Long-term safety data support restricted duration use with appropriate monitoring protocols.